CN101977505A - 类法尼醇x受体激动剂 - Google Patents
类法尼醇x受体激动剂 Download PDFInfo
- Publication number
- CN101977505A CN101977505A CN2008801034987A CN200880103498A CN101977505A CN 101977505 A CN101977505 A CN 101977505A CN 2008801034987 A CN2008801034987 A CN 2008801034987A CN 200880103498 A CN200880103498 A CN 200880103498A CN 101977505 A CN101977505 A CN 101977505A
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- oxygen base
- phenyl
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C**=C[*@](C(C)I)C=CC1=C(C)C=C(CI=CC)*I1 Chemical compound C**=C[*@](C(C)I)C=CC1=C(C)C=C(CI=CC)*I1 0.000 description 16
- GYCHVXCTJVSHLV-UHFFFAOYSA-N CC(C)c1c(COc(cc2)ccc2SCc2cccc3c2cc(C(OC)=O)[s]3)c(-c2c(C3CCC3)cccc2Cl)n[o]1 Chemical compound CC(C)c1c(COc(cc2)ccc2SCc2cccc3c2cc(C(OC)=O)[s]3)c(-c2c(C3CCC3)cccc2Cl)n[o]1 GYCHVXCTJVSHLV-UHFFFAOYSA-N 0.000 description 1
- LQOUVORLVKURMD-UHFFFAOYSA-N CC(C)c1c(COc(cc2)ccc2Sc2cccc3c2cc(C(O)=O)[s]3)c(-c(c(O)ccc2)c2Cl)n[o]1 Chemical compound CC(C)c1c(COc(cc2)ccc2Sc2cccc3c2cc(C(O)=O)[s]3)c(-c(c(O)ccc2)c2Cl)n[o]1 LQOUVORLVKURMD-UHFFFAOYSA-N 0.000 description 1
- UQVLWHVEJOHUDT-UHFFFAOYSA-N CCOC(c1cc(c(Nc(cc2)ccc2OC)ccc2)c2cc1)=O Chemical compound CCOC(c1cc(c(Nc(cc2)ccc2OC)ccc2)c2cc1)=O UQVLWHVEJOHUDT-UHFFFAOYSA-N 0.000 description 1
- LCZCGZQGMZHJKJ-UHFFFAOYSA-N CCOC(c1cc(nc(cc2)-c(cc3)ccc3OCc3ccccc3)c2[s]1)=O Chemical compound CCOC(c1cc(nc(cc2)-c(cc3)ccc3OCc3ccccc3)c2[s]1)=O LCZCGZQGMZHJKJ-UHFFFAOYSA-N 0.000 description 1
- SDHBOTKKSKDSLL-UHFFFAOYSA-N COC(c1cc(cc(cc2)-c(cc3)ccc3O)c2[o]1)=O Chemical compound COC(c1cc(cc(cc2)-c(cc3)ccc3O)c2[o]1)=O SDHBOTKKSKDSLL-UHFFFAOYSA-N 0.000 description 1
- IVIDJLLPQYHHLM-UHFFFAOYSA-N Cc1ccc(CCCC2)c2c1 Chemical compound Cc1ccc(CCCC2)c2c1 IVIDJLLPQYHHLM-UHFFFAOYSA-N 0.000 description 1
- DMJHEIDWSIAXCS-UHFFFAOYSA-N OB(c(cc1)ccc1OCc1ccccc1)O Chemical compound OB(c(cc1)ccc1OCc1ccccc1)O DMJHEIDWSIAXCS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94357307P | 2007-06-13 | 2007-06-13 | |
US60/943,573 | 2007-06-13 | ||
PCT/US2008/066800 WO2008157270A1 (en) | 2007-06-13 | 2008-06-13 | Farnesoid x receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101977505A true CN101977505A (zh) | 2011-02-16 |
Family
ID=40156610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801034987A Pending CN101977505A (zh) | 2007-06-13 | 2008-06-13 | 类法尼醇x受体激动剂 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100249179A1 (de) |
EP (1) | EP2170072A4 (de) |
JP (1) | JP2010529996A (de) |
KR (1) | KR20100038102A (de) |
CN (1) | CN101977505A (de) |
AU (1) | AU2008266154A1 (de) |
BR (1) | BRPI0812521A2 (de) |
CA (1) | CA2689980A1 (de) |
EA (1) | EA200901512A1 (de) |
MX (1) | MX2009013624A (de) |
WO (1) | WO2008157270A1 (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102417483A (zh) * | 2010-09-27 | 2012-04-18 | 中国药科大学 | 作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物 |
CN106946867A (zh) * | 2016-01-06 | 2017-07-14 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
CN107021957A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
CN108072684A (zh) * | 2016-11-11 | 2018-05-25 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
CN108191845A (zh) * | 2018-02-12 | 2018-06-22 | 李化绪 | 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用 |
CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
CN108602811A (zh) * | 2016-02-01 | 2018-09-28 | 山东轩竹医药科技有限公司 | Fxr 受体激动剂 |
CN109906223A (zh) * | 2016-10-04 | 2019-06-18 | 英安塔制药有限公司 | 异噁唑类似物作为fxr激动剂及其使用方法 |
CN110404073A (zh) * | 2013-09-11 | 2019-11-05 | 国家医疗保健研究所 | 治疗乙型肝炎病毒感染的方法和药物组合物 |
CN110922368A (zh) * | 2019-11-29 | 2020-03-27 | 扬州工业职业技术学院 | 一种氯代苯异噁唑氨基苯甲酸衍生物及其制备方法与应用 |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2289883A1 (de) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4) |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2545964A1 (de) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
JP6580074B2 (ja) | 2014-05-23 | 2019-09-25 | アクティブ バイオテック エイビー | S100阻害薬として有用な新規化合物 |
EP3006939A1 (de) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3034499A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Neuartige FXR (NR1H4) modulierende Verbindungen |
EP3034501A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
DK3277286T3 (da) | 2015-03-31 | 2021-07-05 | Enanta Pharm Inc | Galdesydererivater som fxr/tgr5-agonister og anvendelsesmetoder deraf |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
EP3730487B1 (de) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidin abkömmlinge als fxr(nr1h4)-modulierende verbindungen |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
US10654797B2 (en) | 2016-11-03 | 2020-05-19 | North & South Brother Pharmacy Investment Company Limited | Solid forms of an adamantyl compound, compositions and uses thereof |
JP2020508316A (ja) | 2017-02-21 | 2020-03-19 | ジェンフィGenfit | Pparアゴニストとfxrアゴニストとの組合せ |
EP4122464B1 (de) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutische kombinationen zur behandlung von lebererkrankungen |
WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
DK3612520T3 (da) | 2017-04-12 | 2021-12-06 | Il Dong Pharma | Isoxazolderivater som kernereceptoragonister og anvendelser deraf |
JP7148769B2 (ja) * | 2017-09-12 | 2022-10-06 | 学校法人 工学院大学 | 複素環化合物又はその塩、gpr35作動薬及び医薬組成物 |
WO2019089664A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
KR20200083529A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 |
WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
EP4360632A2 (de) | 2019-01-15 | 2024-05-01 | Gilead Sciences, Inc. | Fxr (nr1h4) modulierende verbindungen |
AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
US20240043418A1 (en) | 2020-03-26 | 2024-02-08 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators |
EP4277622A1 (de) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistische wirkung eines fxr-agonisten und ifn zur behandlung von hbv-infektionen |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048349A1 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
CN101374834A (zh) * | 2006-02-03 | 2009-02-25 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
-
2008
- 2008-06-13 US US12/663,722 patent/US20100249179A1/en not_active Abandoned
- 2008-06-13 AU AU2008266154A patent/AU2008266154A1/en not_active Abandoned
- 2008-06-13 BR BRPI0812521-0A patent/BRPI0812521A2/pt not_active IP Right Cessation
- 2008-06-13 KR KR1020107000815A patent/KR20100038102A/ko not_active Application Discontinuation
- 2008-06-13 CN CN2008801034987A patent/CN101977505A/zh active Pending
- 2008-06-13 MX MX2009013624A patent/MX2009013624A/es not_active Application Discontinuation
- 2008-06-13 EA EA200901512A patent/EA200901512A1/ru unknown
- 2008-06-13 CA CA2689980A patent/CA2689980A1/en not_active Abandoned
- 2008-06-13 EP EP08770912A patent/EP2170072A4/de not_active Withdrawn
- 2008-06-13 WO PCT/US2008/066800 patent/WO2008157270A1/en active Application Filing
- 2008-06-13 JP JP2010512368A patent/JP2010529996A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048349A1 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
CN101374834A (zh) * | 2006-02-03 | 2009-02-25 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102417483A (zh) * | 2010-09-27 | 2012-04-18 | 中国药科大学 | 作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物 |
CN110404073A (zh) * | 2013-09-11 | 2019-11-05 | 国家医疗保健研究所 | 治疗乙型肝炎病毒感染的方法和药物组合物 |
CN110404073B (zh) * | 2013-09-11 | 2022-08-16 | 国家医疗保健研究所 | 治疗乙型肝炎病毒感染的方法和药物组合物 |
CN106946867A (zh) * | 2016-01-06 | 2017-07-14 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
CN107021957A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
CN108602811B (zh) * | 2016-02-01 | 2021-11-16 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
CN108602811A (zh) * | 2016-02-01 | 2018-09-28 | 山东轩竹医药科技有限公司 | Fxr 受体激动剂 |
CN109906223A (zh) * | 2016-10-04 | 2019-06-18 | 英安塔制药有限公司 | 异噁唑类似物作为fxr激动剂及其使用方法 |
CN108072684A (zh) * | 2016-11-11 | 2018-05-25 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
CN108072684B (zh) * | 2016-11-11 | 2020-06-16 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
CN108191845A (zh) * | 2018-02-12 | 2018-06-22 | 李化绪 | 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用 |
CN110922368A (zh) * | 2019-11-29 | 2020-03-27 | 扬州工业职业技术学院 | 一种氯代苯异噁唑氨基苯甲酸衍生物及其制备方法与应用 |
CN110922368B (zh) * | 2019-11-29 | 2022-08-16 | 扬州工业职业技术学院 | 一种氯代苯异噁唑氨基苯甲酸衍生物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2689980A1 (en) | 2008-12-24 |
AU2008266154A1 (en) | 2008-12-24 |
KR20100038102A (ko) | 2010-04-12 |
WO2008157270A1 (en) | 2008-12-24 |
MX2009013624A (es) | 2010-04-27 |
BRPI0812521A2 (pt) | 2015-06-23 |
EA200901512A1 (ru) | 2010-06-30 |
EP2170072A1 (de) | 2010-04-07 |
EP2170072A4 (de) | 2010-10-27 |
US20100249179A1 (en) | 2010-09-30 |
JP2010529996A (ja) | 2010-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101977505A (zh) | 类法尼醇x受体激动剂 | |
ES2374165T3 (es) | Agonistas del receptor x farnesoide. | |
ES2428159T3 (es) | Agonistas del receptor X farnesoide | |
CN101877966A (zh) | 类法尼醇x受体激动剂 | |
CN101374835B (zh) | 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法 | |
JP4256150B2 (ja) | エンドテリン介在障害治療用のスルホンアミド類 | |
EP0699191B1 (de) | Sulfonamide und derivate zur modulierung der endothelin aktivitat | |
US9855260B2 (en) | Quinolinone derivatives | |
CN101006065A (zh) | 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 | |
JP2008208143A (ja) | エンドテリン介在障害治療用のスルホンアミド類 | |
WO2011052756A1 (ja) | 新規3-ヒドロキシ-5-アリールイソキサゾール誘導体 | |
TW517057B (en) | Substituted biphenyl isoxazole sulfonamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110216 |